These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

87 related articles for article (PubMed ID: 2739567)

  • 1. Psychometric properties of the Dyskinesia Identification System: Condensed User Scale (DISCUS).
    Sprague RL; Kalachnik JE; Slaw KM
    Ment Retard; 1989 Jun; 27(3):141-8. PubMed ID: 2739567
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The convergent and divergent validity of the Matson Evaluation of Drug Side-effects (MEDS) and the Dyskinesia Identification System: Condensed User Scale (DISCUS).
    Matson JL; Fodstad JC; Rivet TT
    J Intellect Dev Disabil; 2008 Dec; 33(4):337-44. PubMed ID: 19039694
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The dyskinesia Identification System Condensed User Scale (DISCUS): reliability, validity, and a total score cut-off for mentally ill and mentally retarded populations.
    Kalachnik JE; Sprague RL
    J Clin Psychol; 1993 Mar; 49(2):177-89. PubMed ID: 8098048
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Reliability, validity, and a total score cutoff for the dyskinesia identification system: condensed user scale (DISCUS) with mentally ill and mentally retarded populations.
    Sprague RL; Kalachnik JE
    Psychopharmacol Bull; 1991; 27(1):51-8. PubMed ID: 1862206
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The dyskinesia identification system--Coldwater (DIS-Co): a tardive dyskinesia rating scale for the developmentally disabled.
    Sprague RL; Kalachnik JE; Breuning SE; Davis VJ; Ullmann RK; Cullari S; Davidson NA; Ferguson DG; Hoffner BA
    Psychopharmacol Bull; 1984; 20(2):328-38. PubMed ID: 6728999
    [No Abstract]   [Full Text] [Related]  

  • 6. Validation of tardive dyskinesia as measured on the Dyskinesia Identification System--Coldwater.
    Bostrom AC; Walker MK
    Nurs Res; 1990; 39(5):274-9. PubMed ID: 2399131
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Systematic dyskinesia examination of profoundly mentally retarded persons: cooperation and assessment.
    Granger DA; Yurkunski JM; Miller NH; Swanson JM; Crinella FC
    Am J Ment Defic; 1987 Sep; 92(2):155-60. PubMed ID: 2893551
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Predictors of neuroleptic-induced dyskinesia and parkinsonism: the influence of measurement methods and definitions.
    Dean CE; Kuskowski MA; Caligiuri MP
    J Clin Psychopharmacol; 2006 Dec; 26(6):560-5. PubMed ID: 17110811
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Number of nonassessable items and Cooperation level of the retarded during systematic dyskinesia examinations.
    Kalachnik JE; Kidd-Nielsen P; Harder SR
    Psychopharmacol Bull; 1983; 19(1):16-9. PubMed ID: 6828620
    [No Abstract]   [Full Text] [Related]  

  • 10. Dynamics of lip dyskinesia associated with neuroleptic withdrawal.
    Newell KM; Bodfish JW; Mahorney SL; Sprague RL
    Am J Ment Retard; 2000 Jul; 105(4):260-8. PubMed ID: 10934568
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Development of a screening program for tardive dyskinesia: feasibility issues.
    Whall AL; Engle V; Edwards A; Bobel L; Haberland C
    Nurs Res; 1983; 32(3):151-6. PubMed ID: 6133266
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Methods for selecting items in a tardive dyskinesia rating scale.
    Sprague RL; White DM; Ullmann R; Kalachnik JE
    Psychopharmacol Bull; 1984; 20(3):339-45. PubMed ID: 6473627
    [No Abstract]   [Full Text] [Related]  

  • 13. Correlations between kinematic and rating scale measures of tardive dyskinesia in a developmentally disabled population.
    Sprague RL; Korach MS; van Emmerik RE; Newell KM
    J Nerv Ment Dis; 1993 Jan; 181(1):42-7. PubMed ID: 8093476
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Risperidone for severe tardive dyskinesia: a 12-week randomized, double-blind, placebo-controlled study.
    Bai YM; Yu SC; Lin CC
    J Clin Psychiatry; 2003 Nov; 64(11):1342-8. PubMed ID: 14658949
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Substance abuse as a risk factor for tardive dyskinesia: a retrospective analysis of 1,027 patients.
    Bailey LG; Maxwell S; Brandabur MM
    Psychopharmacol Bull; 1997; 33(1):177-81. PubMed ID: 9133772
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Quantification of postural sway patterns in tardive dyskinesia.
    van Emmerik RE; Sprague RL; Newell KM
    Mov Disord; 1993 Jul; 8(3):305-14. PubMed ID: 8101968
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Dyskinetic movement disorder among adults with mental retardation: phenomenology and co-occurrence with stereotypy.
    Bodfish JW; Newell KM; Sprague RL; Harper VN; Lewis MH
    Am J Ment Retard; 1996 Sep; 101(2):118-29. PubMed ID: 8883667
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Antipsychotic drug side effects for persons with intellectual disability.
    Matson JL; Mahan S
    Res Dev Disabil; 2010; 31(6):1570-6. PubMed ID: 20580203
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prevalence of tardive dyskinesia in affective disorder patients.
    Yassa R; Ghadirian AM; Schwartz G
    J Clin Psychiatry; 1983 Nov; 44(11):410-2. PubMed ID: 6139365
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Development of a test battery (NPM-X) for neuropsychological and neuromotor examination of children with developmental disabilities or mental retardation. A theoretical and clinical study.
    Gjaerum B
    Acta Psychiatr Scand Suppl; 1997; 390():1-55. PubMed ID: 9212855
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.